Gavilimomab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Gavilimomab ?
Monoclonal antibody
Type Whole antibody
Source Mouse
Target CD147
Clinical data
Legal status
?
Identifiers
CAS number 244096-20-6 N
ATC code None
Chemical data
Formula ?
 N (what is this?)  (verify)

Gavilimomab (also known as ABX-CBL) is a mouse monoclonal antibody intended for use as an immunosuppressive biologic treatment of glucocorticoid-resistant graft versus host disease. It binds to the antigen CD147.[1] Gavilimomab proved slightly less effective than standard antithymocyte globulin therapy.[2]

It was originally developed by Abgenix,[1] which was later acquired by Amgen.

References[edit]

  1. ^ a b findarticles.com: Sangstat to Provide Clinical Development Update At JP Morgan H&Q Conference in San Francisco
  2. ^ Macmillan, ML; Couriel, D; Weisdorf, DJ; Schwab, G; Havrilla, N; Fleming, TR; Huang, S; Roskos, L et al. (Mar 2007). "A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease". Blood 109 (6): 2657–62. doi:10.1182/blood-2006-08-013995. PMID 17110457.